This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genoptix, Momenta Shares Headed for Gains

BOSTON ( TheStreet) -- Dr. Finny Kuruvilla, manager of the Eventide Gilead Fund (ETGLX), says he's finding strong prospects among health care stocks, such as Momenta Pharmaceuticals (MNTA - Get Report) and Genoptix (GXDX).

The $4.3 million mid-cap growth fund has risen 36% during the past year, outperforming the 29% advance of the S&P 500 Index. The 18-month-old fund beat more than half of competing funds during that time, according to Morningstar (MORN).

Welcome to TheStreet's Fund Manager Five Spot, where America's top mutual fund managers give their best stock picks in five fast and furious questions.

Are you a bull or a bear?

Kuruvilla: If someone forced me to guess, I would say that the market is likely to be choppy in the near term as we digest lots of conflicting data. Longer term, I'm most worried about our political policies being too near-term oriented because major elections are never more than two years away. No one seems to have the grist to advocate for the real reform that we need, such as handling our ballooning debt. In life, it's rare that managing for near-term satisfaction is ever the best thing.

What is your top stock pick?

Kuruvilla: There are at least three or four that jump to mind right away. There's Domtar (UFS - Get Report), which makes paper products in environmentally friendly manner. They collaborate with groups like the World Wildlife Fund to make sure that they operate with best practices. The company has a very attractive valuation and trades with a free cash flow yield of over 20%.

A second is Momenta Pharmaceuticals, which came out of work from the Massachusetts Institute of Technology. They have perhaps the best technology out there for making generics of complex drugs. The Food and Drug Administration may soon be approving their first drug, low molecular-weight heparin, which would be a nice catalyst for the stock. And we badly need more competition in health care to keep drug costs down.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNTA $9.64 3.40%
UFS $38.79 -0.87%
AAPL $93.59 -1.30%
FB $116.27 -0.39%
GOOG $692.35 0.19%


Chart of I:DJI
DOW 17,713.31 -117.45 -0.66%
S&P 500 2,057.71 -18.10 -0.87%
NASDAQ 4,760.3210 -44.97 -0.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs